Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin unveils generic...

    Lupin unveils generic version of Prozac tablets in US

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-24T09:45:27+05:30  |  Updated On 17 Aug 2021 12:08 PM IST

    Fluoxetine tablet is a generic version of Eli Lilly and Company's Prozac tablets in the same strengths, Lupin said.


    Mumba: Pharma major Lupin Limited (Lupin) recently announced the launch of generic antidepressant Fluoxetine tablets in the American market.


    The company has launched Fluoxetine tablets USP in the strengths of 10 mg and 20 mg after having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.


    The product is a generic version of Eli Lilly and Company's Prozac tablets in the same strengths, it added.


    The drug is used for the treatment of a major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder and bulimia nervosa, Lupin said.


    It is indicated in the treatment of:




    • Major Depressive Disorder (MDD)


    Fluoxetine is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to 18 years




    • Obsessive-Compulsive Disorder (OCD)


    Fluoxetine is indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with Obsessive-Compulsive Disorder (OCD)




    • Bulimia Nervosa


    Fluoxetine is indicated for the acute and maintenance treatment of binge‑eating and vomiting behaviours in adult patients with moderate to severe Bulimia Nervosa.




    • Panic Disorder


    Fluoxetine is indicated for the acute treatment of Panic Disorder, with or without agoraphobia, in adult patients.


    Fluoxetine Tablets USP, 10 mg and 20 mg (RLD: Prozac®) had an annual sales of approximately USD 53 million in the US (IQVIA MAT June 2019). Based in Mumbai, Lupin's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.


    Read Also: Lupin gets USFDA approval for generic version of Westcort cream to treat skin conditions

    agoraphobiaantidepressantBulimia Nervosadepression drugdepressive disorderEli LillyFluoxetineLupinmajor depressive disorderMDDobsessive compulsive disorderOCDpanic disorderpediatric patientspharmapharma newspharma news indiaProzacProzac tabletsUnited States Food and Drug AdministrationUSFDA

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok